JP2021522163A5 - - Google Patents
Info
- Publication number
- JP2021522163A5 JP2021522163A5 JP2020556946A JP2020556946A JP2021522163A5 JP 2021522163 A5 JP2021522163 A5 JP 2021522163A5 JP 2020556946 A JP2020556946 A JP 2020556946A JP 2020556946 A JP2020556946 A JP 2020556946A JP 2021522163 A5 JP2021522163 A5 JP 2021522163A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- release composition
- mol
- liposome
- sustained
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862661217P | 2018-04-23 | 2018-04-23 | |
| US62/661,217 | 2018-04-23 | ||
| PCT/US2019/028647 WO2019209787A1 (en) | 2018-04-23 | 2019-04-23 | Inhalable liposomal sustained release composition for use in treating pulmonary diseases |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021522163A JP2021522163A (ja) | 2021-08-30 |
| JPWO2019209787A5 JPWO2019209787A5 (https=) | 2022-04-19 |
| JP2021522163A5 true JP2021522163A5 (https=) | 2022-04-19 |
| JP7391039B2 JP7391039B2 (ja) | 2023-12-04 |
Family
ID=66821301
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020556946A Active JP7391039B2 (ja) | 2018-04-23 | 2019-04-23 | 肺疾患の処置に使用するための吸入可能なリポソーム徐放性組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11534399B2 (https=) |
| EP (1) | EP3784213B1 (https=) |
| JP (1) | JP7391039B2 (https=) |
| KR (1) | KR20210003197A (https=) |
| CN (1) | CN112004527B (https=) |
| AU (1) | AU2019261329B2 (https=) |
| BR (1) | BR112020021412A8 (https=) |
| CA (1) | CA3101102A1 (https=) |
| ES (1) | ES2964413T3 (https=) |
| IL (1) | IL278079B2 (https=) |
| TW (1) | TWI866908B (https=) |
| WO (1) | WO2019209787A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112004527B (zh) | 2018-04-23 | 2024-09-24 | 盈擘生技股份有限公司 | 用于治疗肺部疾病的可吸入脂质体缓释组合物 |
| WO2020055713A1 (en) * | 2018-09-10 | 2020-03-19 | Taiwan Liposome Co., Ltd. | Sustained-release ophthalmic pharmaceutical compositions and uses thereof |
| US12599557B2 (en) | 2019-04-25 | 2026-04-14 | Tlc Biopharmaceuticals, Inc. | Liposomal sustained-release compositions containing a therapeutic drug and use thereof |
| CN114040750B (zh) * | 2019-05-14 | 2025-11-11 | 盈擘生技股份有限公司 | 用于治疗肺部疾病的可吸入支气管扩张剂缓释组合物 |
| TW202143949A (zh) * | 2020-03-22 | 2021-12-01 | 盈擘醫藥股份有限公司 | 用於預防或暴露後治療感染或呼吸疾病的抗病毒組成物 |
| CN112472791A (zh) * | 2020-11-16 | 2021-03-12 | 复旦大学 | CsA脂质体在制备抗SARS-CoV-2药物中的应用 |
| CN116635009A (zh) * | 2020-12-14 | 2023-08-22 | 纳米科技制药公司 | 用于递送抗癌剂的具有改进的治疗指数的组合物和方法 |
| CN114642656B8 (zh) * | 2020-12-18 | 2025-12-12 | 盈科瑞（天津）创新医药研究有限公司 | 一种吸入用尼达尼布溶液及其制备方法 |
| WO2023022520A1 (ko) * | 2021-08-18 | 2023-02-23 | 주식회사 삼양홀딩스 | 룩소리티닙의 경구용 정제 조성물 및 이의 제조 방법 |
| KR102348901B1 (ko) * | 2021-08-26 | 2022-01-07 | 충북대학교 산학협력단 | 레고라페닙을 유효성분으로 포함하는 만성폐쇄성 폐질환의 예방 또는 치료용 조성물 |
| CN116064394A (zh) * | 2021-11-01 | 2023-05-05 | 中国医学科学院医药生物技术研究所 | 肿瘤细胞外泌体与脂质体的杂化外泌体、其制备方法及其抗肿瘤用途 |
| JP2025069482A (ja) * | 2022-03-25 | 2025-05-01 | 国立研究開発法人医薬基盤・健康・栄養研究所 | 特発性肺線維症の治療または予防剤 |
| TW202415382A (zh) * | 2022-09-30 | 2024-04-16 | 大陸商上海濟煜醫藥科技有限公司 | 脂質體藥物組合物及其製備方法和用途 |
| BE1031669B1 (fr) * | 2023-06-02 | 2025-01-14 | Inhatarget Therapeutics | Composition pharmaceutique pour inhalation |
| EP4637764A1 (en) * | 2023-12-22 | 2025-10-29 | Zedira GmbH | Oxo-pyridine derivatives as inhibitors of transglutaminases for use in the treatment of pulmonary fibrosis |
| WO2025138298A1 (zh) * | 2023-12-30 | 2025-07-03 | 北京睿创康泰医药研究院有限公司 | 一种尼达尼布超分子复合体的药物组合物 |
| CN117899020A (zh) * | 2024-01-16 | 2024-04-19 | 中山大学 | 一种载抗生素黏液渗透型脂质体粉雾剂的制备方法及其应用 |
| CN118948812A (zh) * | 2024-08-06 | 2024-11-15 | 北京悦康科创医药科技股份有限公司 | 一种多肽脂质体吸入剂及其制备方法和应用 |
| KR102859152B1 (ko) * | 2024-10-24 | 2025-09-12 | 주식회사 한국리포좀 | 합성 지질 리포좀 기반의 일본 뇌염 바이러스 백신 및 그의 제조방법 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3686025T2 (de) | 1985-05-22 | 1993-01-07 | Liposome Technology Inc | Verfahren und system zum einatmen von liposomen. |
| IE63869B1 (en) | 1986-11-06 | 1995-06-14 | Res Dev Foundation | Aerosols containing liposomes and method for their preparation |
| US5958378A (en) | 1996-07-03 | 1999-09-28 | Research Development Foundation | High dose liposomal aerosol formulations containing cyclosporin A or budesonide |
| GB9912639D0 (en) | 1999-05-28 | 1999-07-28 | Britannia Pharmaceuticals Ltd | Improvements in and relating to treatment of respiratory conditions |
| DE10214983A1 (de) | 2002-04-04 | 2004-04-08 | TransMIT Gesellschaft für Technologietransfer mbH | Vernebelbare Liposomen und ihre Verwendung zur pulmonalen Applikation von Wirkstoffen |
| DE10237423A1 (de) | 2002-08-16 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen |
| EP1581236B1 (en) | 2002-10-29 | 2013-10-16 | Insmed Incorporated | Sustained release of antiinfectives |
| US7718189B2 (en) | 2002-10-29 | 2010-05-18 | Transave, Inc. | Sustained release of antiinfectives |
| KR20060015265A (ko) * | 2003-05-30 | 2006-02-16 | 알자 코포레이션 | 제제의 폐 투여 방법 |
| PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| HUE029994T2 (en) | 2005-12-08 | 2017-04-28 | Insmed Inc | Lipid-based compositions of antiinfectives for treating pulmonary infections |
| US8071127B2 (en) | 2006-10-24 | 2011-12-06 | Aradigm Corporation | Dual action, inhaled formulations providing both an immediate and sustained release profile |
| US8119156B2 (en) | 2006-10-24 | 2012-02-21 | Aradigm Corporation | Dual action, inhaled formulations providing both an immediate and sustained release profile |
| US8268347B1 (en) | 2006-10-24 | 2012-09-18 | Aradigm Corporation | Dual action, inhaled formulations providing both an immediate and sustained release profile |
| US9333214B2 (en) | 2007-05-07 | 2016-05-10 | Insmed Incorporated | Method for treating pulmonary disorders with liposomal amikacin formulations |
| JP2010540498A (ja) * | 2007-09-28 | 2010-12-24 | ウニヴェルズィテーツシュピタール バーゼル | 癌の治療のための免疫リポソーム |
| WO2012027727A2 (en) * | 2010-08-26 | 2012-03-01 | Kunyuan Cui | Lipomacrocycles and uses thereof |
| WO2012031603A2 (en) | 2010-09-09 | 2012-03-15 | Danish Medical Consults Aps | Airway administration of angiogenesis inhibitors |
| MX2011007675A (es) | 2011-07-19 | 2012-07-11 | Cell Therapy And Technology S A De C V | Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas. |
| EP4309657A3 (en) * | 2013-02-01 | 2024-02-28 | Celator Pharmaceuticals, Inc. | Remote loading of sparingly water-soluble drugs into liposomes |
| JP6799201B2 (ja) * | 2013-07-31 | 2020-12-16 | アヴァリン ファーマ インク． | エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用 |
| KR20150026613A (ko) * | 2013-09-03 | 2015-03-11 | 삼성전자주식회사 | 소수성 물질 및 조영제를 포함하는 리포좀 및 그의 용도 |
| NZ760541A (en) | 2014-01-10 | 2022-08-26 | Avalyn Pharma Inc | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| WO2016090111A1 (en) | 2014-12-05 | 2016-06-09 | Vindico NanoBio Technology Inc. | Compositions and methods for inducing nanoparticle-mediated microvascular embolization of tumors |
| WO2016178064A1 (en) | 2015-05-06 | 2016-11-10 | Suven Life Sciences Limited | Polymorph of nintedanib ethanesulphonate, processes and intermediates thereof |
| US20180344644A1 (en) * | 2015-09-21 | 2018-12-06 | Mallinckrodt Llc | Improved stability of liposome formulations and uses thereof |
| CN108601746B (zh) * | 2016-01-08 | 2024-09-13 | 加利福尼亚大学董事会 | 用于运载物递送的具有脂质双层包衣的中孔二氧化硅纳米颗粒 |
| CA3013768A1 (en) * | 2016-02-04 | 2017-08-10 | Stem Cell Theranostics, Inc. | Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity |
| CN112004527B (zh) | 2018-04-23 | 2024-09-24 | 盈擘生技股份有限公司 | 用于治疗肺部疾病的可吸入脂质体缓释组合物 |
-
2019
- 2019-04-23 CN CN201980027748.1A patent/CN112004527B/zh active Active
- 2019-04-23 WO PCT/US2019/028647 patent/WO2019209787A1/en not_active Ceased
- 2019-04-23 CA CA3101102A patent/CA3101102A1/en active Pending
- 2019-04-23 TW TW108114188A patent/TWI866908B/zh active
- 2019-04-23 EP EP19729872.2A patent/EP3784213B1/en active Active
- 2019-04-23 US US17/045,940 patent/US11534399B2/en active Active
- 2019-04-23 KR KR1020207033553A patent/KR20210003197A/ko not_active Ceased
- 2019-04-23 JP JP2020556946A patent/JP7391039B2/ja active Active
- 2019-04-23 ES ES19729872T patent/ES2964413T3/es active Active
- 2019-04-23 IL IL278079A patent/IL278079B2/en unknown
- 2019-04-23 BR BR112020021412A patent/BR112020021412A8/pt unknown
- 2019-04-23 AU AU2019261329A patent/AU2019261329B2/en active Active
-
2022
- 2022-11-22 US US17/992,481 patent/US12533313B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021522163A5 (https=) | ||
| IL278079B1 (en) | Inhalable liposomal sustained release compound for use in the treatment of pulmonary diseases | |
| JP6974670B2 (ja) | 弱酸性薬物を含むリポソーム組成物およびその使用 | |
| JPWO2019209787A5 (https=) | ||
| JP6357481B2 (ja) | プロスタサイクリン化合物およびプロスタサイクリン化合物を使用する方法 | |
| US5741516A (en) | Sphingosomes for enhanced drug delivery | |
| WO2015138423A1 (en) | Prostacylin compositions and methods for using the same | |
| JP2014506918A (ja) | 抗腫瘍活性物質を含むリポソーム製剤、その調製のための方法、及び、それを含む医薬組成物 | |
| JP4833836B2 (ja) | リポソーム製剤 | |
| JP4874097B2 (ja) | 水難溶性カンプトテシン含有リポソーム製剤 | |
| TWI757739B (zh) | 包含弱酸藥物之醫藥組成物及其用途 | |
| US11083693B1 (en) | Liposome formulation of vilanterol trifenatate | |
| HK40043569A (en) | Inhalable liposomal sustained release composition for use in treating pulmonary diseases | |
| TW202604536A (zh) | 霧化器套組及其用途 | |
| US20210059937A1 (en) | Liposome Formulation of Fluticasone Furoate and Method of Preparation | |
| TW202547521A (zh) | 全身性硬化症與凍傷的吸入治療方法 | |
| WO2025264889A1 (en) | Nebulizer kits and uses thereof | |
| HK40043569B (zh) | 用於治疗肺部疾病的可吸入脂质体缓释组合物 | |
| Johnston | Studies of factors influencing drug efflux rates from liposomes and their impact on antitumor efficacy |